Your browser doesn't support javascript.
loading
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment.
Tripodi, A.
Affiliation
  • Tripodi A; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano and IRCCS Maggiore Hospital Foundation, Milan, Italy.
J Thromb Haemost ; 15(9): 1882-1883, 2017 09.
Article in En | MEDLINE | ID: mdl-28585328
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Dabigatran Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Dabigatran Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: Italy